The Pharmacy Times® Lung Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that begins on the lungs, including non-small cell lung cancer and small cell lung cancer.
May 7th 2024
Pharmacists can raise awareness for lung cancer during and after Lung Cancer Action Week.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung Cancer
1.5 Credits / Lung Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Practice Behavior Changes After Approval of Durvalumab in Review of Insurance Claims
September 16th 2021Dr. Jason Liu and his colleagues hoped to assess the use of maintenance durvalumab based on patient and physician characteristics among individuals with stage 3 NSCLC in the United States.
Read More
Imfinzi Shows Significant Survival Benefit in Phase 3 Trial for Non-Small Cell Lung Cancer
September 10th 2021Results from POSEIDON, a randomized open label, phase 3 trial, showed that patients administered 5 cycles of tremelimumab plus durvalumab and chemotherapy over 16 weeks experienced a 23% reduction in the risk of death compared with various chemotherapy options.
Read More
The investigators found that the combination of cemiplimab-rwlc and chemotherapy resulted in a substantial improvement in OS compared to chemotherapy alone for patients with metastatic or locally advanced disease and tumors with either squamous or non-squamous histology and across all programmed death-ligand 1 expression levels.
Read More
FDA Grants Atezolizumab Priority Review as Adjuvant Treatment for Certain Patients With NSCLC
August 3rd 2021According to a press release from Roche, the FDA is reviewing the company’s Biologics License Application under the Real-Time Oncology Review pilot program, which aims to explore a more efficient review process to ensure safe and effective treatments are available to patients as early as possible.
Read More